Please enable JS

Patients

Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior safety and efficacy profiles compared to currently marketed drugs.

Utilizing our proprietary MIDAS technology, we have developed a portfolio of promising drug candidates that target the following therapeutic indications:

Indication

Lead Compound

Onychomycosis

VT-1161

Recurrent Vulvovaginal Candidiasis (RVVC)

VT-1161

Cryptococcal Meningitis

VT-1129

Valley Fever

VT-1598

Hospital-based, Invasive Fungal Infections

Multiple compounds